Following Malta's accession to the European Patent Convention early last month, the Federation received several requests for the clarification of Malta's patent situation with regard to the operations of the generic pharmaceutical manufacturing firms based in Malta.
To this end, the FOI organised a well-attended briefing for its members operating in this sector who were addressed by senior officials from Malta Enterprise. During the discussions, reference was also made to the Bolar provisions and any forthcoming changes to Maltese legislation that would affect manufacturers of generic medicines in Malta.